Page 2 - Lustgarten Laboratory News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Investigators develop novel treatment for T-cell leukemias and lymphomas

Investigators develop novel treatment for T-cell leukemias and lymphomas
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Suman paulTushard nichakawadeTushar nichakawadeJohns hopkins kimmel cancer centerLustgarten laboratoryLudwig centerJohns hopkins university school of medicineJohns hopkins university school

Researchers develop new technology to reduce high error rates in gene sequencing

Researchers develop new technology to reduce high error rates in gene sequencing Next-generation gene sequencing (NGS) technologies in which millions of DNA molecules are simultaneously but individually analyzed theoretically provides researchers and clinicians the ability to noninvasively identify mutations in the blood stream. Identifying such mutations enables earlier diagnosis of cancer and can inform treatment decisions. Johns Hopkins Kimmel Cancer Center researchers developed a new technology to overcome the inefficiencies and high error rates common among next-generation sequencing techniques that have previously limited their clinical application. To correct for these sequencing errors, the research team from the Ludwig Center and Lustgarten Laboratory at the Johns Hopkins Kimmel Cancer Center developed SaferSeqS (Safer Sequencing System), a major improvement to widely used technologies based on a previous technology called SafeSeqS (Safe Sequencing System) that Hopkins i

Joshua cohenEmily hendersonLudwig centerJohns hopkins kimmel cancer centerLustgarten laboratoryHopkins kimmel cancer centerSafer sequencing systemSafe sequencing systemStudy lead authorGene sequencingஜோஷுவா கோஹன்எமிலி ஹென்டர்சன்லுட்விக் மையம்ஜான்ஸ் ஹாப்கின்ஸ் கீம்மேல் புற்றுநோய் மையம்ஹாப்கின்ஸ் கீம்மேல் புற்றுநோய் மையம்படிப்பு வழி நடத்து நூலாசிரியர்

Hopkins-led research team takes gene mutation detection in blood to the next level

E-Mail IMAGE: New SaferSeqS technology detects rare mutations in blood in a highly efficient manner and reduces the error rate. view more Credit: Elizabeth Cooke Next-generation gene sequencing (NGS) technologies in which millions of DNA molecules are simultaneously but individually analyzed theoretically provides researchers and clinicians the ability to noninvasively identify mutations in the blood stream. Identifying such mutations enables earlier diagnosis of cancer and can inform treatment decisions. Johns Hopkins Kimmel Cancer Center researchers developed a new technology to overcome the inefficiencies and high error rates common among next-generation sequencing techniques that have previously limited their clinical application. To correct for these sequencing errors, the research team from the Ludwig Center and Lustgarten Laboratory at the Johns Hopkins Kimmel Cancer Center developed SaferSeqS (Safer Sequencing System), a major improvement to widely used tec

United statesJanine ptakCristian tomasettiMaria popoliJoshua cohenJonathanc dudleyNickolas papadopoulosBert vogelsteinJohns hopkins christopher douvilleKenneth kinzlerPeter gibbsLisa dobbynNatalie sillimanJohns hopkins universityTranslational research grantNational institutes of health

Mutant Gene-Targeted Immunotherapy Approach Developed

share: This news release, issued by Johns Hopkins Medicine, describes a novel targeted immunotherapy approach. This new approach employs bispecific antibodies to treat cancer by eliciting a Tcell response against mutated p53. The researchers used the Highly Automated Macromolecular Crystallography (AMX) and Frontier Microfocusing Macromolecular Crystallography (FMX) beamlines to characterize the molecular structure of the proteins. AMX and FMX are beamlines at the National Synchrotron Light Source II (NSLS-II) a U.S. Department of Energy (DOE) Office of Science User Facility at Brookhaven National Laboratory. NSLS-II offers a comprehensive suite of life science research capabilities. Johns Hopkins media contacts: Amy Mone, 410-614-2915, amone@jhmi.edu, or Valerie Mehl, 410-614-2916, mehlva@jhmi.edu. Brookhaven Lab media contacts: Cara Laasch, 631-344-8458, laasch@bnl.gov or Peter Genzer, 631-344-3174, genzer@bnl.gov.

United statesMichaelb murphyShibin zhouValerie mehlEmily hanNickolas papadopoulosMichael hwangEvangeline watsonKatharine wrightAstra zeneca medimmune amplimmuneKatharinem wrightYana liElizabeth cookPatricka brownGabriel ghiaurBristol myers squibb

New cancer immunotherapy uses engineered T cells to target a common genetic alteration

New cancer immunotherapy uses engineered T cells to target a common genetic alteration Researchers developed a prototype for a new cancer immunotherapy that uses engineered T cells to target a genetic alteration common among all cancers. The approach, which stimulates an immune response against cells that are missing one gene copy, called loss of heterozygosity (LOH), was developed by researchers at the Ludwig Center, Lustgarten Laboratory and the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center. Genes have two alleles, or copies, with one copy inherited from each parent. Cancer-related genetic alterations commonly involve the loss of one of these gene copies.

Kenneth kinzlerShibin zhouMichael hwangBert vogelsteinEmily hendersonLudwig centerBloomberg kimmel institute for cancer immunotherapyJohns hopkins kimmel cancer centerProceedings of the national academy sciencesJohns hopkins university school of medicineLustgarten laboratoryKimmel instituteJohns hopkins kimmel cancerNational academyJohns hopkins university schoolBrian mog